Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA consumer warning

This article was originally published in The Tan Sheet

Executive Summary

The dietary supplements Emagrece Sim and Herbathin should not be used and should be returned to suppliers because they "may contain several active ingredients, including controlled substances, found in prescription drugs that could lead to serious side effects or injury," the agency announces Jan. 13. FDA has issued an import alert to prevent importation of the products, which are made in Brazil by the firms Fitoterapicos and Phytotherm Sim. The products contain fluoxetine HCl (Prozac) and chlordiazepoxide HCl (Librium), which are used to relieve anxiety, according to FDA. They also were found to contain Fenproporex, a stimulant that is "not approved for marketing in the U.S." and is converted in the body to amphetamine. The supplements are sold on the Internet, and FDA is "aware of commercial imports of these products and individuals importing them for personal use"...

You may also be interested in...



Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

International Harmonization: Not Just For Audits Anymore

The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.

Reddy’s Settles On $7bn Revlimid But Natco Maintains The Lead

Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.

Topics

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel